Astellas is committed to providing timely and accurate information about our business, science and products. This section offers local resources for investors, journalists and media professionals. Global news and resources can be viewed here. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
ATLANTA, June 5 /PRNewswire-FirstCall/ -- Genentech, Inc. (NYSE: DNA) and OSI Pharmaceuticals (Nasdaq: OSIP) today presented results from a Phase II study that compared the combinations of...
First Arginine Vasopressin (AVP) Antagonist Approved for the Management of Potentially Life-Threatening Sodium and Water Imbalance PRNewswire DEERFIELD, Ill. Astellas Pharma US, Inc. today...
MELVILLE, N.Y.--(BUSINESS WIRE)--April 17, 2006--OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that a New Drug Application has been submitted in Japan covering the use of its flagship...
Acquisition of psoriasis product deepens Astellas’ Commitment to Dermatology franchise Deerfield, IL and Cambridge, MA, April 3, 2006 – Astellas Pharma US, Inc. and Biogen Idec Inc. (NASDAQ:...
Heart indication for Prograf reinforces a 20-year commitment to research and development in transplantation DEERFIELD, IL, APRIL 1, 2006 – The Food and Drug Administration (FDA) has granted...
Follow U.S. news
